Age years -median (range) |
11 (3-18) |
12 (6-15) |
0.39 |
Female gender N (%) |
9 (53) |
2 (15) |
0.0575 |
Time since COVID-19 Diagnosis (months) |
5 (2-11) |
3 (2-8) |
0.89 |
Duration of PASC symptoms (months)* |
5 (2-11) |
N/A |
N/A |
COVID-19 Severity N (%) |
COVID-19 Severity N (%) |
COVID-19 Severity
N (%) |
|
Moderate |
17(100) |
13(100) |
N/A |
SARS-CoV-2 vaccination |
0 |
0 |
N/A |
Variant of concern N (%) |
Variant of concern N (%) |
Variant of
concern N (%) |
|
WT |
10 (59) |
7(54) |
1 |
Alpha |
7 (41) |
6 (46) |
0.8167 |
PASC Type |
PASC Type |
PASC Type |
|
Ongoing COVID-19 |
0 |
N/A |
N/A |
Post-acute COVID-19 Syndrome |
17 (100) |
N/A |
N/A |